Clear cell carcinomas of the ovary: A multi-institutional study of 129 cases in Korea with prognostic significance of emi1 and galectin-3

International Journal of Gynecological Pathology

Volumn 32, Issue 1, 2013, Pages 3-14

  Min, Kyueng Whan ^a   Park, Moon Hyang ^a   Hong, Sung Ran ^b   Lee, Heejung ^c   Kwon, Sun Young ^d   Hong, Sook Hee ^e   Joo, Hee Jae ^f   Park, In Ae ^g   An, Hee Jung ^h   Suh, Kwang Sun ⁱ   Oh, Hoon Kyu ^j   Yoo, Chong Woo ^k   Kim, Mi Jin ^l   Chang, Hee Kyung ^m   Jun, Sun Young ⁿ   Yoon, Hye Kyoung ^o   Chang, Eun Deok ^p   Kim, Dong Won ^q   Kim, Insun ^r  

^a Hanyang University   (South Korea)

^b Catholic Kwandong University   (South Korea)

^c The Catholic University of Korea   (South Korea)

^d Keimyung University   (South Korea)

^e Dong A University   (South Korea)

^f Ajou University   (South Korea)

^g Seoul National University   (South Korea)

^h CHA University   (South Korea)

ⁱ Chungnam National University   (South Korea)

^j Catholic University of Daegu   (South Korea)

^k National Cancer Center   (South Korea)

^l Yeungnam University   (South Korea)

^m Kosin University   (South Korea)

ⁿ Hallym University   (South Korea)

^o Inje University   (South Korea)

^p Uijeongbu St Mary's Hospital   (South Korea)

^q Soonchunhyang University   (South Korea)

^r Korea University   (South Korea)

more..

Author keywords

Clear cell carcinoma; Emi1 protein; Galectin 3; Ki 67 antigen; Ovarian cancer; p53 antigen

Indexed keywords

ANTINEOPLASTIC AGENT; CELL CYCLE PROTEIN; EARLY MITOTIC INHIBITOR 1 PROTEIN; ESTROGEN RECEPTOR; GALECTIN 3; HEPATOCYTE NUCLEAR FACTOR 1BETA; KI 67 ANTIGEN; PROTEIN P53; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLEAR CELL CARCINOMA; DISEASE FREE SURVIVAL; ENDOMETRIOSIS; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KOREA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OVARY CARCINOMA; OVARY CLEAR CELL CARCINOMA; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSAMMOMA BODY; SCORING SYSTEM; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA, CLEAR CELL; ADULT; AGED; CELL CYCLE PROTEINS; DISEASE-FREE SURVIVAL; F-BOX PROTEINS; FEMALE; GALECTIN 3; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; KOREA; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84871659005     PISSN: 02771691     EISSN: 15387151     Source Type: Journal    
DOI: 10.1097/PGP.0b013e31825554e9     Document Type: Article

References (34)

1. FIGO (International Federation of Gynecology and Obstetrics). 26th Annual Report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 2006;95(suppl 1): S1-S257.
2. Behbakht K, Randall TC, Benjamin I, et al. Clinical characteristics of clear cell carcinoma of the ovary. Gynecol Oncol 1998;70:255-8. (Pubitemid 28430939)
3. Itamochi H, Kigawa J, Sugiyama T, et al. Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary. Obstet Gynecol 2002;100:281-7. (Pubitemid 34874791)
4. Mizuno M, Kikkawa F, Shibata K, et al. Long-term follow-up and prognostic factor analysis in clear cell adenocarcinoma of the ovary. J Surg Oncol 2006;94:138-143. (Pubitemid 44267195)
5. Sugiyama T, Kamura T, Kigawa J, et al. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 2000;88:2584-9. (Pubitemid 30331967)
6. TakanoM, Kikuchi Y, Yaegashi N, et al. Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging. Br J Cancer 2006;94:1369-74. (Pubitemid 43772268)
7. Oishi T, Itamochi H, Kigawa J, et al. Galectin-3 may contribute to Cisplatin resistance in clear cell carcinoma of the ovary. Int J Gynecol Cancer 2007;17:1040-6. (Pubitemid 47414828)
8. Mazurek N, Sun YJ, Price JE, et al. Phosphorylation of galectin-3 contributes to malignant transformation of human epithelial cells via modulation of unique sets of genes. Cancer Res 2005;65:10767-75. (Pubitemid 41713345)
9. Lehman NL, Verschuren EW, Hsu JY, et al. Overexpression of the anaphase promoting complex/cyclosome inhibitor Emi1 leads to tetraploidy and genomic instability of p53- deficient cells. Cell Cycle 2006;5:1569-73. (Pubitemid 44091978)
10. Hsu JY, Reimann JD, Sorensen CS, et al. E2F-dependent accumulation of hEmi1 regulates S phase entry by inhibiting APC(Cdh1). Nat Cell Biol 2002;4:358-6. (Pubitemid 34521031)
11. Gutgemann I, Lehman NL, Jackson PK, et al. Emi1 protein accumulation implicates misregulation of the anaphase promoting complex/cyclosome pathway in ovarian clear cell carcinoma. Mod Pathol 2008;21:445-4. (Pubitemid 351441034)
12. Anreder MB, Freeman SM, Merogi A, et al. p53, c-erbB2, and PCNA status in benign, proliferative and malignant ovarian surface epithelial neoplasms: a study of 75 cases. Arch Pathol Lab Med 1999;123:310-6. (Pubitemid 29172064)
13. Geisler JP, Geisler HE, Wiemann MC, et al. Quantification of p53 in epithelial ovarian cancer. Gynecol Oncol 1997;66:435-8. (Pubitemid 27388136)
14. Yamamoto S, Tsuda H, Takano M, et al. Clear-cell adenofibroma can be a clonal precursor for clear-cell adenocarcinoma of the ovary: a possible alternative ovarian clear-cell carcinogenic pathway. J Pathol 2008;216:103-10.
15. McCluggage WG. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. Pathology 2011;43:420-32.
16. Kajihara H, Yamada Y, Kanayama S, et al. Clear cell carcinoma of the ovary: potential pathogenic mechanisms (Review). Oncol Rep 2010;23:1193-203.
17. Silverberg SG. Histopathologic grading of ovarian carcinoma: a review and proposal. Int J Gynecol Pathol 2000;19:7-15. (Pubitemid 30010638)
18. Ishioka S, Sagae S, Terasawa K, et al. Comparison of the usefulness between a new universal grading system for epithelial ovarian cancer and the FIGO grading system. Gynecol Oncol 2003;89:447-52. (Pubitemid 36687791)
19. Ryu SY, Park SI, Nam BH, et al. Prognostic significance of histological grade in clear-cell carcinoma of the ovary: a retrospective study of Korean Gynecologic Oncology Group. Ann Oncol 2009;20:1032-6.
20. Shimizu Y, Kamoi S, Amada S, et al. Toward the development of a universal grading system for ovarian epithelial carcinoma. I. Prognostic significance of histopathologic features - problems involved in the architectural grading system. Gynecol Oncol 1998;70:2-12. (Pubitemid 28368866)
21. Gilks CB, Ionescu DN, Kalloger SE, et al. Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. Hum Pathol 2008;39:1239-51.
22. Levine AJ, Perry ME, Chang A, et al. The 1993 Walter Hubert Lecture: the role of the p53 tumour-suppressor gene in tumorigenesis. Br J Cancer 1994;69:409-16.
23. Akahane T, Sekizawa A, Purwosunu Y, et al. The role of p53 mutation in the carcinomas arising from endometriosis. Int J Gynecol Pathol 2007;26:345-51. (Pubitemid 46986074)
24. Sainz de la Cuesta R, Izquierdo M, Canamero M, et al. Increased prevalence of p53 overexpression from typical endometriosis to atypical endometriosis and ovarian cancer associated with endometriosis. Eur J Obstet Gynecol Reprod Biol 2004;113:87-93. (Pubitemid 38281201)
25. Kobayashi H, Kajiwara H, Kanayama S, et al. Molecular pathogenesis of endometriosis-associated clear cell carcinoma of the ovary (review). Oncol Rep 2009;22:233-40.
26. Fernandes Bertocchi AP, Campanhole G, Wang PH, et al. A role for galectin-3 in renal tissue damage triggered by ischemia and reperfusion injury. Transplant Int 2008;21:999-1007.
27. Raz A, Zhu DG, Hogan V, et al. Evidence for the role of 34- kDa galactoside-binding lectin in transformation and metastasis. Int J Cancer 1990;46:871-7.
28. Nangia-Makker P, Honjo Y, Sarvis R, et al. Galectin-3 induces endothelial cell morphogenesis and angiogenesis. Am J Pathol 2000;156:899-909. (Pubitemid 30626949)
29. Xu XC, el-Naggar AK, Lotan R. Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications. Am J Pathol 1995;147: 815-22.
30. Lotan R, Ito H, Yasui W, et al. Expression of a 31-kDa lactoside-binding lectin in normal human gastric mucosa and in primary and metastatic gastric carcinomas. Int J Cancer 1994;56:474-80. (Pubitemid 24094396)
31. Hsu DK, Dowling CA, Jeng KC, et al. Galectin-3 expression is induced in cirrhotic liver and hepatocellular carcinoma. Int J Cancer 1999;81:519-26. (Pubitemid 29203046)
32. Kim MK, Sung CO, Do IG, et al. Overexpression of galectin-3 and its clinical significance in ovarian carcinoma. Int J Clin Oncol 2011;16:352-8.
33. Lee JH, Zhang X, Shin BK, et al. Mac-2 binding protein and galectin-3 expression in mucinous tumours of the ovary: an annealing control primer system and immunohistochemical study. Pathology 2009;41:229-33.
34. Lehman NL, Tibshirani R, Hsu JY, et al. Oncogenic regulators and substrates of the anaphase promoting complex/cyclosome are frequently overexpressed in malignant tumors. Am J Pathol 2007;170:1793-805. (Pubitemid 47339321)